Q1 2027 Emcure Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Revenue grew 22.8% year-on-year to INR 2,580 crores, with strong growth across all geographies.
- EBITDA grew 25.8% to INR 508 crores, with margins improving by 50 basis points to 19.7%.
- Profit after tax grew 35.4% to INR 292 crores, with PAT margin improving by 110 basis points.
- International business delivered robust growth of 34.2%, with Europe, Canada, and Rest of World all contributing strongly.
- The company acquired full ownership of its biotech arm, Genova, and received 15+ product approvals, strengthening its pipeline and strategic control.
- Gross margin declined year-over-year to 68.4%, impacted by an increased export mix and product mix.
- Domestic organic growth, excluding in-licensed products, was only 6-7%, below the industry average.
- Net debt increased due to working capital and is expected to rise further in the next quarter due to acquisition payouts.
- The domestic business is still recovering from the Zuventus restructuring, with growth expected to align with the industry only from the next quarter.
- The semaglutide launch in Canada is delayed due to a partner's issue, with revised timelines uncertain.
Ladies and gentlemen, good day and welcome to the Emcure Pharmaceuticals Limited U1 FY27 Earnings Conference Call.
(Operator Instructions)
I now hand the conference over to Mr. Saurabh Paliwal, Head of Investor Relations.
Thank you and over to you, sir.
Thank you, Dorwin. Good afternoon, everyone, and welcome to Q1 FY '27 earnings conference call of Empire Pharmaceuticals.
We will begin today's session with opening remarks from the management, followed by a Q&A session.
Joining me today on this call are Mr. Satish Mehta, Managing Director and CEO Mr. Tajuddin Shaikh, Chief Finance Officer. Mr. Samit Mehta , full-time Director and COO Mr. Vik Thapar, President, Corporate Development Strategy and Finance and Mr. Piyush Nahar, Executive Vice President, Corporate Development and Strategy.
We hope you had the opportunity to review the financial results, the results presentation, and the press release, which was released earlier this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
